Literature DB >> 22633815

EORTC Radiation Oncology Group quality assurance platform: establishment of a digital central review facility.

Alysa Fairchild1, Edwin Aird, Paul A Fenton, Vincent Gregoire, Akos Gulyban, Denis Lacombe, Oscar Matzinger, Philip Poortmans, Pascal Ruyskart, Damien C Weber, Coen W Hurkmans.   

Abstract

OBJECTIVE: Quality assurance (QA) in clinical trials is essential to ensure treatment is safely and effectively delivered. As QA requirements have increased in complexity in parallel with evolution of radiation therapy (RT) delivery, a need to facilitate digital data exchange emerged. Our objective is to present the platform developed for the integration and standardization of QART activities across all EORTC trials involving RT.
METHODS: The following essential requirements were identified: secure and easy access without on-site software installation; integration within the existing EORTC clinical remote data capture system; and the ability to both customize the platform to specific studies and adapt to future needs. After retrospective testing within several clinical trials, the platform was introduced in phases to participating sites and QART study reviewers.
RESULTS: The resulting QA platform, integrating RT analysis software installed at EORTC Headquarters, permits timely, secure, and fully digital central DICOM-RT based data review. Participating sites submit data through a standard secure upload webpage. Supplemental information is submitted in parallel through web-based forms. An internal quality check by the QART office verifies data consistency, formatting, and anonymization. QART reviewers have remote access through a terminal server. Reviewers evaluate submissions for protocol compliance through an online evaluation matrix. Comments are collected by the coordinating centre and institutions are informed of the results.
CONCLUSIONS: This web-based central review platform facilitates rapid, extensive, and prospective QART review. This reduces the risk that trial outcomes are compromised through inadequate radiotherapy and facilitates correlation of results with clinical outcomes.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Mesh:

Year:  2012        PMID: 22633815     DOI: 10.1016/j.radonc.2012.04.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

2.  Analyzing magnetic resonance imaging data from glioma patients using deep learning.

Authors:  Bjoern Menze; Fabian Isensee; Roland Wiest; Bene Wiestler; Klaus Maier-Hein; Mauricio Reyes; Spyridon Bakas
Journal:  Comput Med Imaging Graph       Date:  2020-12-02       Impact factor: 4.790

3.  Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial.

Authors:  Erik Roelofs; Lucas Persoon; Sebastiaan Nijsten; Wolfgang Wiessler; André Dekker; Philippe Lambin
Journal:  Radiother Oncol       Date:  2013-02-05       Impact factor: 6.280

4.  Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.

Authors:  André N Abrunhosa-Branquinho; Raquel Bar-Deroma; Sandra Collette; Enrico Clementel; Yan Liu; Coen W Hurkmans; Loïc Feuvret; Karen Van Beek; Martin van den Bent; Brigitta G Baumert; Damien C Weber
Journal:  Radiother Oncol       Date:  2018-03-29       Impact factor: 6.280

5.  Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials.

Authors:  Christopher G Willett; Jennifer Moughan; Elizabeth O'Meara; James M Galvin; Christopher H Crane; Kathryn Winter; Denise Manfredi; Tyvin A Rich; Rachel Rabinovitch; Robert Lustig; Mitchell Machtay; Walter J Curran
Journal:  Radiother Oncol       Date:  2012-10-17       Impact factor: 6.280

6.  Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective.

Authors:  Marie Lambrecht; Christos Melidis; Jan-Jakob Sonke; Sonja Adebahr; Ronald Boellaard; Marcel Verheij; Matthias Guckenberger; Ursula Nestle; Coen Hurkmans
Journal:  Radiat Oncol       Date:  2016-01-20       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.